Larimar Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Larimar Therapeutics

14/03/2024 21:46

* Larimar Therapeutics Inc  LRMR.OQ  reported a quarterly
adjusted
loss of 30 cents​​ per share for the quarter ended in December,
lower than the same quarter last year, when the company reported
EPS of -21 cents.  The mean expectation of five analysts for the
quarter was for a loss of 25 cents per share. Wall Street
expected results to range from -28 cents to -22 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Larimar Therapeutics Inc's reported EPS for the quarter
was a
loss of 30 cents​.
    * The company reported a quarterly loss of $12.99 million.
    * Larimar Therapeutics Inc shares had risen by 104.4% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Larimar
Therapeutics Inc is $25.00 

This summary was machine generated from LSEG data March 14 at
09:45 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.25          -0.30          Missed
 Sep. 30 2023      -0.22          -0.21          Beat
 Jun. 30 2023      -0.19          -0.19          Met
 Mar. 31 2023      -0.25          -0.15          Beat